Cyclo Therapeutics, Inc (CYTH) Enterprise Value to EBITDA Ratio

Public company logo of cyclotherapeutics.com (CYTH)

The EV/EBITDA valuation chart allows for an assessment of Cyclo Therapeutics (CYTH), whose advantages are based on exclusive rights to Trappsol Cyclo for the treatment of Niemann-Pick disease. The current metric stands at . The business relies on US laboratories and innovative drug development methods. FDA breakthrough therapy status strengthens the company's position in a narrow niche where patients have virtually no treatment alternatives.

Cyclo Therapeutics Inc. - CYTH Company Value to EBITDA (period 07/04/2022 - 11/12/2026)

Comprehensive metric breakdowns and analytics for cyclotherapeutics.com (CYTH)

- current price and projected stock value:
Stock Price CTD Holdings|CYTH - Analyst Median Target
- market capitalization details:
Market Valuation Cyclo Therapeutics, Inc|CYTH - Full Business Value
- business book valuation details:
Book Value per Share Cyclo Therapeutics|CYTH - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cyclotherapeutics.com|CYTH - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Cyclo Therapeutics|CYTH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cyclo Therapeutics, Inc.|CYTH - Company Aggregate Indebtedness|Debts to Book Capitalization Cyclo Therapeutics, Inc|CYTH - Company Long-Term Loans and Borrowings|Company Short-Term Debts Cyclo Therapeutics|Quick Liquidity cyclotherapeutics.com
- financial results and valuation multiples details:
CYTH - Final Profit|Expected Profit Cyclo Therapeutics|CYTH - Price to Earnings Ratio|Forward P/E Multiple Cyclo Therapeutics|CYTH - PEG Multiple|EV/EBITDA Multiple Cyclo Therapeutics, Inc|CYTH - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Cyclo Therapeutics|CYTH - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth cyclotherapeutics.com|CYTH - Net earnings per share growth this year|Net earnings per share growth forecast for next year Cyclo Therapeutics
Fundamental valuation:CTD Holdings CYTH
Manufactured products of Cyclo Therapeutics, Inc.

This indicator compares the total enterprise value, including net debt, with its operating profit before taxes. By analyzing the EV/EBITDA multiple on a time chart, an investor determines the market overvaluation of assets relative to their ability to generate cash flow. For Cyclo Therapeutics (CYTH), this metric is extremely sensitive, as the lack of pricing power during the clinical trial stage makes future capitalization dependent solely on FDA approval.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Aytu BioPharma Inc AYTU|Chemomab - EV/EBITDA Multiple|SRx Health Solutions Inc. (SRXH) - Enterprise Value to EBITDA Ratio|PLRZ (polyrizon-biotech.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Aeterna Zentaris Inc. (AEZS)|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio reneopharma.com (RPHM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COSCIENS Biopharma (CSCI)